PETER HOTEZ to Cost-Benefit Analysis
This is a "connection" page, showing publications PETER HOTEZ has written about Cost-Benefit Analysis.
Connection Strength
0.852
-
What Is the Economic Benefit of Annual COVID-19 Vaccination From the Adult Individual Perspective? J Infect Dis. 2024 Aug 16; 230(2):382-393.
Score: 0.179
-
Lives and Costs Saved by Expanding and Expediting Coronavirus Disease 2019 Vaccination. J Infect Dis. 2021 09 17; 224(6):938-948.
Score: 0.146
-
The Potential Economic Value of a Zika Vaccine for a Woman of Childbearing Age. Am J Prev Med. 2020 03; 58(3):370-377.
Score: 0.130
-
What Is the Value of Different Zika Vaccination Strategies to Prevent and Mitigate Zika Outbreaks? J Infect Dis. 2019 08 09; 220(6):920-931.
Score: 0.126
-
Saving lives efficiently across sectors: the need for a Congressional cost-effectiveness committee. Lancet. 2017 Nov 25; 390(10110):2410-2412.
Score: 0.109
-
Rescuing the bottom billion through control of neglected tropical diseases. Lancet. 2009 May 02; 373(9674):1570-5.
Score: 0.062
-
The potential economic value of a therapeutic Chagas disease vaccine for pregnant women to prevent congenital transmission. Vaccine. 2020 04 03; 38(16):3261-3270.
Score: 0.033
-
Economic value of a therapeutic Chagas vaccine for indeterminate and Chagasic cardiomyopathy patients. Vaccine. 2019 06 19; 37(28):3704-3714.
Score: 0.031
-
Modeling the economic and epidemiologic impact of hookworm vaccine and mass drug administration (MDA) in Brazil, a high transmission setting. Vaccine. 2016 Apr 27; 34(19):2197-206.
Score: 0.025
-
"Rapid-impact interventions": how a policy of integrated control for Africa's neglected tropical diseases could benefit the poor. PLoS Med. 2005 Nov; 2(11):e336.
Score: 0.012